Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 8/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28344053 | 0.92 | ALB (0.42) | ALBCA1CA2TDP1ATM | |
| SCHEMBL17646353 | 0.92 | ALB (0.42) | ALBCA1CA2TDP1ATM | |
| SCHEMBL19983222 | 0.91 | CA1 (0.42) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL28172916 | 0.91 | ALB (0.52) | ALBCA1CA2TDP1NPSR1 | |
| SCHEMBL17646270 | 0.91 | ALB (0.52) | ALBCA1CA2TDP1NPSR1 | |
| SCHEMBL18236311 | 0.90 | TDP1 (0.46) | ALBCA1CA2TDP1ATM | |
| SCHEMBL17646338 | 0.88 | ALB (0.42) | ALBCA1CA2TDP1ATM | |
| SCHEMBL19688865 | 0.88 | ALB (0.42) | ALBCA1CA2TDP1ATM | |
| SCHEMBL17646346 | 0.88 | ALB (0.42) | ALBCA1CA2TDP1ATM | |
| SCHEMBL19665648 | 0.88 | ALB (0.42) | ALBCA1CA2TDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | ALB 4774/4885CA1 262/4885CA2 893/4885 |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | ALB 4774/4885CA1 262/4885CA2 893/4885 |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | ALB 4774/4885CA1 262/4885CA2 893/4885 |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | ALB 4774/4885CA1 262/4885CA2 893/4885 |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | ALB 4774/4885CA1 262/4885CA2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.